Brief Introduction

Hunan Nucien Pharmaceutical, founded in December 2006, is an innovative pharmaceutical company focusing on the R & D, manufacturing and marketing of small molecule medicines. At present, the company has 34 product lines, 53 drug registration approvals and 8 API registration approvals, including 3 exclusive products and 9 exclusive dosage forms or specifications. Its main products include antivirals、cardiovascular drugs、antibiotics and other products. The company's class 1.1 innovative drug, peramivir sodium chloride injection, has been recognized by the market after several years of marketing, and now enjoys a strong competitive edge for the treatment of influenza.

Company Overview

Full name Hunan Nucien Pharmaceutical Co., Ltd.
Abbreviations NUCIEN PHARMA
Code 688189
Founded 27.Dec.2006
Listing 26.Mar.2020
Domicile No.1 Kangli Road, Liuyang Economic and Technological Development Zone, Changsha, Hunan.
Website www.nucien.com
Email nanxin@nucien.com
STAR Theme Biomedicine
CSRCSector Manufacturing
Has weighted voting rights structure? No

Financials

Highlights

  2018 2017 2016
Earnings Per Share 0.46 0.12 0.04
R&D expenditure as a % of operating revenue 6.46% 6.35% 5.93%
Operating Revenue 700.52 347.52 278.20
Net Income 62.44 37.18 21.24

Income Statement (Unit: RMB mn)

  2018 2017 2016
Operating Revenue 700.52 347.52 278.20
Operating Costs 639.63 315.49 261.52
Operating Income 59.91 37.56 15.46
Pretax Income 63.97 37.35 25.52
Income Tax 1.53 0.17 4.28
Net Income 62.44 37.18 21.24

Balance Sheet(Unit: RMB mn)

  2018 2017 2016
Assets
Current Assets-Total 284.73 170.32 203.63
Non-current Assets-Total 411.32 436.42 410.90
Total Assets 696.05 606.75 614.53
Liabilities
Current Liabilities-Total 283.39 325.28 327.16
Non-current Liabilities-Total 147.85 79.08 116.18
Total Liabilities 431.23 404.36 443.35
Stockholder's Equity
Share Capital 105.00 105.00 210.00
Retained Profits -73.86 -127.38 -259.53
Total Owners' Equity 234.30 180.78 153.63

Cash Flow Statement (Unit: RMB mn)

  2018 2017 2016
Net Cash Flows-Operating 64.41 70.72 75.35
Net Cash Flows-Investing -21.18 -46.49 -28.48
Net Cash Flows-Financing 6.89 -52.71 10.15

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
湖南湘投控股集团有限公司 40 28.57%
广州乾元投资管理企业(有限合伙) 22 15.71%
杭州鼎晖新趋势股权投资合伙企业(有限合伙) 15 10.71%
湖南湘江大健康创业投资合伙企业(有限合伙) 5 3.57%
湖南省厚水投资合伙企业(有限合伙) 4.5 3.21%
杭州信为玺泰投资合伙企业(有限合伙) 4.5 3.21%
深圳市键宁银创投资有限公司 4.205 3.00%
深圳市汇尚致鑫实业管理中心(有限合伙) 3 2.14%
叶胜利 2.795 2.00%
广州霆霖投资咨询有限公司 2 1.43%
 

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.